Anisomycin

Research use only, not for human use.

An antibiotic that inhibits eukaryotic protein synthesis by inhibiting peptidyl transferase or the 80S ribosome system.

An antibiotic that inhibits eukaryotic protein synthesis by inhibiting peptidyl transferase or the 80S ribosome system; sensitizes RCC cells to DR4-mediated apoptosis through the induction of DR4.(In Vitro):To examine whether JNK has a core role in colistin-induced neurotoxicity in PC-12 cells, an SP600125 (a highly selective inhibitor of JNK) and Anisomycin (a potent activator) are used in this study. In order to select an appropriate concentration, PC-12 cells are treated with a range of SP600125 (0-80 μM) and Anisomycin (0-20 μM) respectively for 24 h. The results show that the cells viability significantly decreases by SP600125 treatment in a concentration-dependent manner, observed at the concentrations greater than 20 μM (p<0.01). Similarly the cells viability is inhibited by Anisomycin treatment (≥8 μM) (p<0.05) .(In Vivo):Anisomycin (60 mg/kg; for 4-week continuous intravenous administration) significantly decreases mouse body weight in a dose-related manner, compared with the control group. Anisomycin (15 mg/kg; for 4-week continuous intravenous administration) slightly and transiently decreases the mouse body weight. There is no significant difference of the mouse body weight in 5 mg/kg group.

To examine whether JNK has a core role in colistin-induced neurotoxicity in PC-12 cells, an SP600125 (a highly selective inhibitor of JNK) and Anisomycin (a potent activator) are used in this study. In order to select an appropriate concentration, PC-12 cells are treated with a range of SP600125 (0-80 μM) and Anisomycin (0-20 μM) respectively for 24 h. The results show that the cells viability significantly decreases by SP600125 treatment in a concentration-dependent manner, observed at the concentrations greater than 20 μM (p<0.01). Similarly the cells viability is inhibited by Anisomycin treatment (≥8 μM) (p<0.05) .

Anisomycin (60 mg/kg; for 4-week continuous intravenous administration) significantly decreases mouse body weight in a dose-related manner, compared with the control group. Anisomycin (15 mg/kg; for 4-week continuous intravenous administration) slightly and transiently decreases the mouse body weight. There is no significant difference of the mouse body weight in 5 mg/kg group. Animal Model:Balb/c mice of both sexes (4-5 weeks old)Dosage:84, 99, 116, 136 or 160 mg/kg; 0.2 mL per mouse Administration:Intravenously injected through mouse tail vein Result:The calculated LD50 for Anisomycin was 119.64 mg/kg.

Flagecidin | Wuningmeisu C

GPCR/G Protein

Antibacterial

JNK

Infection

——

22862-76-6

265.305

C14H19NO4

>98% (HPLC)

10 mM in DMSO

O[C@@H]1[C@@H](OC(C)=O)[C@@H](CC2=CC=C(OC)C=C2)NC1

3,4-Pyrrolidinediol, 2-[(4-methoxyphenyl)methyl]-, 3-acetate, (2R,3S,4S)-

(-20℃)

With Ice Pack

≥ 2 years